Organ Care System (OCS) Lung System
TransMedics, Inc. · Decision date Oct 28, 2026
What did the FDA decide?
FDA records a 30-day notice supplement, P160013/S023, for the Organ Care System (OCS™) Lung System, with decision OK30 dated 2026-10-28. The stated change is "a change in supplier and mold transfer of the bellows, a component of the OCS Lung System." The notice is filed under the supplement reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The product code is listed as QBA, and the applicant is TransMedics, Inc.
The identifier ties this supplement to the original PMA P160013; the notice covers a supplier change and mold transfer for one named part rather than an approval of the full system. The supplied fields do not identify the old or new supplier, describe the mold transfer, or provide verification data, so no conclusion about safety or clinical effect follows from the notice itself. The specialty fields read Gastroenterology, Urology, while the device category describes donor lung preservation, an inconsistency the record does not explain.
FDA approval order statement
a change in supplier and mold transfer of the bellows, a component of the OCS Lung System
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Oct 28, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P160013/S023
- Regulatory pathway
- PMA supplement
- Applicant
- TransMedics, Inc.
- Product code
- QBA
- Decision code
- OK30
- Decision date
- Oct 28, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Normothermic machine perfusion system for the preservation of standard criteria donor lungs prior to transplantation.
- Applicant
- TransMedics, Inc.
- Product code
- QBA
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P160013. Subsequent supplements may change the device or its indications.
FDA decision timeline
P160013 · Original PMA
Organ Care System (OCS) Lung System
P160013/S023 received
Application receipt date recorded by FDA.
P160013/S023 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P160013. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160013
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| TransMedics, Inc. | PMA approval | Mar 22, 2018 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
TransMedics, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 200 Minuteman Rd., Suite 302, Andover, MA, 01810
Sources and methodology
- Original FDA record: P160013/S023
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records